Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne
NCT06316297Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Apr 2024
- Primary completion
- Nov 2028
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised trial of Acne mRNA vaccine in acne vulgaris (8 cohorts), sponsored by Sanofi. Primary endpoints: Number of participants with unsolicited systemic Adverse Events at 30 minutes, Number of participants with solicited injection site and systemic reactions at 7 days and 8 more. Started Apr 2024; status: recruiting.
02
Drugs
Acne mRNA vaccine
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT06316297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316297.